|
General description:
The Molecular Pathology Unit on the IFOM-IEO Campus for Oncogenomics uses a high throughput screening technology (Tissue Microarrays, TMA) together with in situ detection methods (ISH and IHC) to identify novel putative cancer targets for drug discovery, diagnostic and/or prognostic applications.
|
Specific service:
Within RUBICON, Partner IFOM offers initial screening analysis on multitumor Tissue Microarrays containing more than 300 formalin-fixed and paraffin-embedded samples from different common tumor histotypes and related non-pathologic tissue. Analysis of gene expression on TMAs can be performed either by using RNA-in situ hybridisation or immuno-histochemistry (probes and protocols to be provided by partner labs).
Advanced screens (on a collaborative basis only):
 | large scale screens (for interesting protein families)
|
| validation of ad-hoc screens
|
| in-depth analysis (e.g. retrospective cancer studies).
|
To access the Core facility files (Rubicon-members only!):
1.
| scroll to the bottom of this page and click 'login'
| 2.
| Click on the 'documents' drop down menu (top right hand side), and select the 'core facility' folder. Within this folder you will find the 'Expression Profiling' folder.
|
|
|
|
|
Core Facilities
Expression profiling by tissue microarray